These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 34016077)

  • 1. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
    Maghsoomi Z; Emami Z; Malboosbaf R; Malek M; Khamseh ME
    BMC Cancer; 2021 May; 21(1):579. PubMed ID: 34016077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide Receptor Radionuclide Therapy in Patients With Differentiated Thyroid Cancer: A Meta-analysis.
    Lee DY; Kim YI
    Clin Nucl Med; 2020 Aug; 45(8):604-610. PubMed ID: 32520503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience.
    Satapathy S; Mittal BR; Sood A; Verma R; Panda N
    Nucl Med Commun; 2020 Jul; 41(7):629-635. PubMed ID: 32371670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.
    Teunissen JJ; Kwekkeboom DJ; Kooij PP; Bakker WH; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():107S-14S. PubMed ID: 15653659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors.
    Liu Q; Kulkarni HR; Zhao T; Schuchardt C; Chen X; Zhu Z; Zhang J; Baum RP
    Clin Nucl Med; 2023 Mar; 48(3):221-227. PubMed ID: 36723881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medullary thyroid carcinoma (MTC) treated with 177Lu-DOTATATE PRRT: a report of two cases.
    Makis W; McCann K; McEwan AJ
    Clin Nucl Med; 2015 May; 40(5):408-12. PubMed ID: 25674858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls.
    Beukhof CM; Brabander T; van Nederveen FH; van Velthuysen MF; de Rijke YB; Hofland LJ; Franssen GJH; Fröberg LAC; Kam BLR; Visser WE; de Herder WW; Peeters RP
    BMC Cancer; 2019 Apr; 19(1):325. PubMed ID: 30953466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
    Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
    Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
    [No Abstract]   [Full Text] [Related]  

  • 9. Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy.
    Hayes AR; Crawford A; Al Riyami K; Tang C; Bomanji J; Baldeweg SE; Wild D; Morganstein D; Harry A; Grozinsky-Glasberg S; Oleinikov K; Khoo B; Caplin ME; Nicolas GP; Grossman AB
    J Clin Endocrinol Metab; 2021 Nov; 106(12):e4903-e4916. PubMed ID: 34379772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma.
    Dadgar H; Jafari E; Ahmadzadehfar H; Rekabpour SJ; Ravanbod MR; Kalantarhormozi M; Nabipour I; Assadi M
    Ann Endocrinol (Paris); 2023 Feb; 84(1):45-51. PubMed ID: 36126757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utility of
    Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
    Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.
    Wassermann J; Bernier MO; Spano JP; Lepoutre-Lussey C; Buffet C; Simon JM; Ménégaux F; Tissier F; Leban M; Leenhardt L
    Oncologist; 2016 Jan; 21(1):50-8. PubMed ID: 26675742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients.
    Versari A; Sollini M; Frasoldati A; Fraternali A; Filice A; Froio A; Asti M; Fioroni F; Cremonini N; Putzer D; Erba PA
    Thyroid; 2014 Apr; 24(4):715-26. PubMed ID: 24102584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?
    Campennì A; Pignata SA; Baldari S
    Endocrine; 2015 Nov; 50(2):516-8. PubMed ID: 25471282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy.
    Gao Z; Biersack HJ; Ezziddin S; Logvinski T; An R
    J Cancer Res Clin Oncol; 2004 Nov; 130(11):649-56. PubMed ID: 15300425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide receptor radionuclide therapy of differentiated thyroid cancer: efficacy and toxicity.
    Czepczyński R; Matysiak-Grześ M; Gryczyńska M; Bączyk M; Wyszomirska A; Stajgis M; Ruchała M
    Arch Immunol Ther Exp (Warsz); 2015 Apr; 63(2):147-54. PubMed ID: 25403743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
    Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
    Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
    Gupta SK; Singla S; Bal C
    Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
    Bodei L; Handkiewicz-Junak D; Grana C; Mazzetta C; Rocca P; Bartolomei M; Lopera Sierra M; Cremonesi M; Chinol M; Mäcke HR; Paganelli G
    Cancer Biother Radiopharm; 2004 Feb; 19(1):65-71. PubMed ID: 15068613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.